Your browser doesn't support javascript.
loading
Identification and Validation of Compounds Selectively Killing Resistant Cancer: Delineating Cell Line-Specific Effects from P-Glycoprotein-Induced Toxicity.
Füredi, András; Tóth, Szilárd; Szebényi, Kornélia; Pape, Veronika F S; Türk, Dóra; Kucsma, Nóra; Cervenak, László; Tóvári, József; Szakács, Gergely.
Afiliación
  • Füredi A; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
  • Tóth S; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
  • Szebényi K; Institute of Cancer Research, Medical University of Vienna, Vienna, Austria.
  • Pape VF; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
  • Türk D; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
  • Kucsma N; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary.
  • Cervenak L; 3rd Department of Medicine Research Laboratory, Semmelweis University, Budapest, Hungary.
  • Tóvári J; Department of Experimental Pharmacology, National Institute of Oncology, Budapest, Hungary.
  • Szakács G; Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary. szakacs.gergely@ttk.mta.hu.
Mol Cancer Ther ; 16(1): 45-56, 2017 01.
Article en En | MEDLINE | ID: mdl-27760838
Despite significant progress, resistance to chemotherapy is still the main reason why cancer remains a deadly disease. An attractive strategy is to target the collateral sensitivity of otherwise multidrug resistant (MDR) cancer. In this study, our aim was to catalog various compounds that were reported to elicit increased toxicity in P-glycoprotein (Pgp)-overexpressing MDR cells. We show that the activity of most of the serendipitously identified compounds reported to target MDR cells is in fact cell-line specific, and is not influenced significantly by the function of Pgp. In contrast, novel 8-hydroxyquinoline derivatives that we identify in the National Cancer Institute (NCI) drug repository possess a robust Pgp-dependent toxic activity across diverse cell lines. Pgp expression associated with the resistance of the doxorubicin-resistant Brca1-/-;p53-/- spontaneous mouse mammary carcinoma cells could be eliminated by a single treatment with NSC57969, suggesting that MDR-selective compounds can effectively revert the MDR phenotype of cells expressing Pgp at clinically relevant levels. The discovery of new MDR-selective compounds shows the potential of this emerging technology and highlights the 8-hydroxyquinoline scaffold as a promising starting point for the development of compounds targeting the Achilles heel of drug-resistant cancer. Mol Cancer Ther; 16(1); 45-56. ©2016 AACR.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Resistencia a Antineoplásicos / Descubrimiento de Drogas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Resistencia a Antineoplásicos / Descubrimiento de Drogas / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Estados Unidos